Despite the global economic slowdown, biologics managed single-digit growth in 2008, driven mainly by continued high growth in sales of antibodies and insulins. Novel biologics in development look promising, but crowding, pricing and reimbursement are emerging as longer-term concerns.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Cre-LoxP-regulated expression of monoclonal antibodies driven by an ovalbumin promoter in primary oviduct cells
BMC Biotechnology Open Access 14 January 2011
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Aggarwal, S. Nat. Biotechnol. 26, 1227–1233 (2008).
Anonymous. IMS Health Reports U.S. Prescription Sales Grew 1.3 Percent in 2008 to $291 Billion. IMS, Norwalk, CT, USA, March 19, 2009. http://www.imshealth.com/portal/site/imshealth/ menuitem.a46c6d4df3db4b3d88f611019418c22a/ ?vgnextoid=078ce5b87da10210VgnVCM100000ed152ca2RCRD& vgnextchannel=41a67900b55a5110VgnVCM10000071812ca2 RCRD&vgnextfmt=default
Aggarwal, S. Nat. Biotechnol. 25, 1097–1104 (2007).
Spaide, R.F. et al. Retina 26, 383–390 (2006).
Kenneth, R.C. et al. Blood 113, 4834–4840 (2009).
Leavitt, M.O. A Design for a Bundled End Stage Renal Disease Prospective Payment System. Report to Congress, 2008.http://www.cms.hhs.gov/ESRDGeneralInformation/downloads/ ESRDReportToCongress.pdf
United States Government Accountability Office Report to Congressional Committees. Bundling Medicare's Payment for Drugs with Payment for All ESRD Services Would Promote Efficiency and Clinical Flexibility (US GAO, Washington, DC, USA, 2006) http://www.gao.gov/products/GAO-07-77
Jonasson, J.M. et al. Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden. Diabetologia. 52, 1745–1754 (2009).
Rosenstock, J. et al. Diabetologia 52, 1971–1973 (2009).
Cohen, J. et al. Oral fingolimod (FTY720) versus interferon β-1a in relapsing-remitting multiple sclerosis: results from a Phase III study (TRANSFORMS). Slide deck associated with oral presentation at the American Academy of Neurology Annual Meeting 2009, Seattle, April 25–May 2, 2009.
Babbit, B., Nick, C. & Aggarwal, S. Product Development Strategies for Follow-on Biologics Part II, Windhover, Norwalk, CT, April 23, 2009. http://www.windhover.com/ezine/html/ac0409-lp.htm
Rights and permissions
About this article
Cite this article
Aggarwal, S. What's fueling the biotech engine—2008. Nat Biotechnol 27, 987–993 (2009). https://doi.org/10.1038/nbt1109-987
This article is cited by
Recombinant Antibody Production in CHO and NS0 Cells: Differences and Similarities
Molecular pharming’s foot in the FDA’s door: Protalix’s trailblazing story
Biotechnology Letters (2015)
Growth and production of microencapsulated recombinant CHO in a stirred tank bioreactor
Bioprocess and Biosystems Engineering (2015)
What's fueling the biotech engine—2012 to 2013
Nature Biotechnology (2014)
What's fueling the biotech engine—2011 to 2012
Nature Biotechnology (2012)